Sequencing-grade screening for BRCA1 variants by oligo-arrays
2008

New Method for Screening BRCA1 Variants

Sample size: 85 publication Evidence: high

Author Information

Author(s): Alessandro Monaco, Filippo Menolascina, Yingdong Zhao, Stefania Tommasi, Marianna Sabatino, Ross Fasano, Angelo Paradiso, Francesco M Marincola, Ena Wang

Primary Institution: Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA

Hypothesis

Can an oligo-nucleotide array-based process effectively screen for BRCA1 genetic variants?

Conclusion

The oligo-nucleotide array method is an accurate and efficient strategy for detecting BRCA1 variants, significantly reducing time and costs compared to traditional sequencing.

Supporting Evidence

  • The oligo-array detected 15 non-synonymous, 4 synonymous, and 10 intronic SNPs.
  • The method showed complete concordance with sequencing for 83 out of 85 patient samples.
  • The oligo-array can analyze the entire BRCA1 gene in one reaction.

Takeaway

Scientists created a new test to find genetic changes that can cause breast cancer, and it works faster and cheaper than older methods.

Methodology

The study used an oligo-nucleotide array to detect SNPs and gene rearrangements in the BRCA1 gene from patient samples.

Limitations

The accuracy of the oligo-array was only confirmed for one fragment of the BRCA1 locus.

Participant Demographics

Patients with familial breast and/or ovarian cancer, classified as having a higher than 10% probability of carrying a BRCA1 or BRCA2 mutation.

Statistical Information

P-Value

0.05

Statistical Significance

p = 0.05

Digital Object Identifier (DOI)

10.1186/1479-5876-6-64

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication